We are looking for partners in new drug development.

We are seeking partners for two matters.

1. Out-licensing

1) Oral Atopic Dermatitis Drug for Companion Animals(Phase 3)

: we have potential best-in-class orally JAK1 inhibitor for Atopic Dermatitis in companion animails.

We are developing a safer alternative to Apoquel, now in a pivotal Phase 3 trial in Korea, and we're targeting 25 Million EUR in domestic sales alone

2) Topical Atopic Dermatitis Drug for Human(Phase 2)

: we have potential best-in-class topical JAK1 inhibitor for Atopic Dermatitis with a strategic focus on indication expansion into the pediatric population . It's uniquely positioned to be the first in its class to potentially avoid a black box warning. We've completed Phase 1 in Korea and are now entering Phase 2

3) Oncology Drug (Preclinical)

: We have a preclinical HPK1 inhibitor designed to enhance T-cell based cancer therapies

4) Oral Psoriasis Drug (Preclinical)

: we have a preclinical, orally available allosteric TYK2 inhibitor for Psoriasis. We believe its allosteric mechanism gives it a compelling, best-in-class potential with a superior safety profile.

2. In-licensing

1) Obesity Treatments

2) Cardiovascular and Metabolic Disease Treatments

3) Novel Mechanism of Action (MOA) Drugs